Janssen-cilag International Nv

This study tested if people with moderate-to-severe plaque psoriasis who responded very well to the drug guselkumab could safely receive their injections less often—every 16 weeks instead of every 8—and still keep their skin clear. It involved 880 participants and looked at skin …